WuXi’s API production site in china passes USFDA’s inspection

WuXi STA Pharmaceutical’s Active Pharmaceutical Ingredient (API) production site in China, at Jinshan, Shanghai, has passed its fourth inspection from the U.S. Food and Drug Administration (USFDA). WuXi STA is the first CDMO in China that is approved to supply commercial APIs for innovative drugs by regulatory agencies in the USA, China, EU, Canada, Switzerland, Australia, and New Zealand.

Mei Hao, Vice President of Quality at WuXi STA, said: “We are very proud of successfully passing the FDA inspection once more. Quality is ingrained throughout our culture and, whilst fully expected, further demonstrates our commitment to customers and patients worldwide.”

Dr. Minzhang Chen, CEO of WuXi STA said: “It is an integral part of the company’s culture to exceed global standards. We will continue to put quality first for all of our worldwide partners and offer them integrated efficient and flexible solutions, accelerating the process of new drug launches.”